Abstract
The high prevalence of vitamin D deficiency in postmenopausal women starting adjuvant Aromatase Inhibitors (AI) supports the hypothesis that hypovitaminosis D would be one of the biological explanations for the adverse effects of AI. These condition, even as cancer-related fatigue (CRF), may be related to poor Health-Related Quality of Life (HRQoL) in breast cancer (BC) survivors during adjuvant endocrine therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
